Peptide vaccines

Peptide vaccines are composed of one or more microbial proteinaceous antigens that, when administered, elicit protective immunity against the microbial pathogen.

Latest Research and Reviews

  • Research |

    Neoantigen-targeting vaccines are a feasible therapy for tumours with a low mutation burden and immunologically ‘cold’ tumour microenvironment, as neoantigen-specific T cells from the peripheral blood migrate into intracranial glioblastoma, thereby altering the immune milieu of the glioblastoma.

    • Derin B. Keskin
    • , Annabelle J. Anandappa
    • , Jing Sun
    • , Itay Tirosh
    • , Nathan D. Mathewson
    • , Shuqiang Li
    • , Giacomo Oliveira
    • , Anita Giobbie-Hurder
    • , Kristen Felt
    • , Evisa Gjini
    • , Sachet A. Shukla
    • , Zhuting Hu
    • , Letitia Li
    • , Phuong M. Le
    • , Rosa L. Allesøe
    • , Alyssa R. Richman
    • , Monika S. Kowalczyk
    • , Sara Abdelrahman
    • , Jack E. Geduldig
    • , Sarah Charbonneau
    • , Kristine Pelton
    • , J. Bryan Iorgulescu
    • , Liudmila Elagina
    • , Wandi Zhang
    • , Oriol Olive
    • , Christine McCluskey
    • , Lars R. Olsen
    • , Jonathan Stevens
    • , William J. Lane
    • , Andres M. Salazar
    • , Heather Daley
    • , Patrick Y. Wen
    • , E. Antonio Chiocca
    • , Maegan Harden
    • , Niall J. Lennon
    • , Stacey Gabriel
    • , Gad Getz
    • , Eric S. Lander
    • , Aviv Regev
    • , Jerome Ritz
    • , Donna Neuberg
    • , Scott J. Rodig
    • , Keith L. Ligon
    • , Mario L. Suvà
    • , Kai W. Wucherpfennig
    • , Nir Hacohen
    • , Edward F. Fritsch
    • , Kenneth J. Livak
    • , Patrick A. Ott
    • , Catherine J. Wu
    •  & David A. Reardon
    Nature 565, 234-239
  • Research | | open

    Tumours can escape CD8 T-cell immunity by down-regulating antigen presentation machinery components, such as TAP. Here the authors describe tumour antigenic peptides processed by TAP-independent and -dependent pathways and show in mouse models that these peptides can be exploited to induce antitumor T-cell activity when TAP expression is downregulated.

    • Aurélie Durgeau
    • , Yasemin Virk
    • , Gwendoline Gros
    • , Elodie Voilin
    • , Stéphanie Corgnac
    • , Fayçal Djenidi
    • , Jérôme Salmon
    • , Julien Adam
    • , Vincent de Montpréville
    • , Pierre Validire
    • , Soldano Ferrone
    • , Salem Chouaib
    • , Alexander Eggermont
    • , Jean-Charles Soria
    • , François Lemonnier
    • , Eric Tartour
    • , Nathalie Chaput
    • , Benjamin Besse
    •  & Fathia Mami-Chouaib
  • Research | | open

    • Tommy Rampling
    • , Katie J. Ewer
    • , Georgina Bowyer
    • , Nick J. Edwards
    • , Danny Wright
    • , Saranya Sridhar
    • , Ruth Payne
    • , Jonathan Powlson
    • , Carly Bliss
    • , Navin Venkatraman
    • , Ian D. Poulton
    • , Hans de Graaf
    • , Diane Gbesemete
    • , Amy Grobbelaar
    • , Huw Davies
    • , Rachel Roberts
    • , Brian Angus
    • , Karen Ivinson
    • , Rich Weltzin
    • , Bebi-Yassin Rajkumar
    • , Ulrike Wille-Reece
    • , Cynthia Lee
    • , Chris Ockenhouse
    • , Robert E. Sinden
    • , Stephen C. Gerry
    • , Alison M. Lawrie
    • , Johan Vekemans
    • , Danielle Morelle
    • , Marc Lievens
    • , Ripley W. Ballou
    • , David J. M. Lewis
    • , Graham S. Cooke
    • , Saul N. Faust
    • , Sarah Gilbert
    •  & Adrian V. S Hill
    npj Vaccines 3, 49

News and Comment